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Biofilm formation is a major virulence attribute of Candida pathogenicity which contributes to higher
antifungal resistance. We investigated the roles of cell density and cellular aging on the relative antifungal
susceptibility of planktonic, biofilm, and biofilm-derived planktonic modes of Candida. A reference and a
wild-type strain of Candida albicans were used to evaluate the MICs of caspofungin (CAS), amphotericin B
(AMB), nystatin (NYT), ketoconazole (KTC), and flucytosine (5FC). Standard, NCCLS, and European Com-
mittee on Antibiotic Susceptibility Testing methods were used for planktonic MIC determination. Candida
biofilms were then developed on polystyrene wells, and MICs were determined with a standard 2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide assay. Subsequently,
antifungal susceptibility testing was performed for greater inoculum concentrations and 24- and 48-h-old
cultures of planktonic Candida. Furthermore, Candida biofilm-derived planktonic cells (BDPC) were also
subjected to antifungal susceptibility testing. The MICs for both C. albicans strains in the planktonic mode
were low, although on increasing the inoculum concentration (up to 1  108 cells/ml), a variable MIC was
noted. On the contrary, for Candida biofilms, the MICs of antifungals were 15- to >1,000-fold higher.
Interestingly, the MICs for BDPC were lower and were similar to those for planktonic-mode cells, particularly
those of CAS and AMB. Our data indicate that higher antifungal resistance of Candida biofilms is an intrinsic
feature possibly related to the biofilm architecture rather than cellular density or cellular aging.
Candida is by far the most important fungal pathogen of
humans, causing diseases varying from superficial mucosal in-
fections to life-threatening systemic disorders (34). Candida
infections have been documented as a leading cause of noso-
comial infection, with reported mortality rates as high as 40%
(6, 41, 42). Further, prevailing in many guises, Candida causes
significant mortality and morbidity in compromised patient
populations such as human immunodeficiency virus/AIDS pa-
tients and organ transplant recipients on immunosuppressive
therapy (33).
Candida infections primarily begin with adherence and col-
onization of an artificial or a biotic host surface, leading to the
formation of surface-attached communities known as biofilms.
These structured communities, encased in a matrix of exopoly-
meric substances, display unique characteristics that confer
survival advantages over their planktonic counterparts (12, 14).
Indeed, it has been documented that at least 65% of all mi-
crobial infections are related to biofilms (29). Candida can
develop biofilms on almost all medical devices in current use,
including stents, shunts, prostheses (voice box, heart valves,
dentures, etc.), implants (lens, breast, etc.), and various types
of catheters (31).
The major clinical relevance of Candida biofilms, and in fact
of all microbial biofilms, is their high resistance to antimicro-
bials. Candida biofilms are known to exhibit elevated antifun-
gal resistance compared to their planktonic counterparts in
liquid culture for a number of antifungal agents including am-
photericin B (AMB), fluconazole, itraconazole, and ketoco-
nazole (KTC) (3, 11, 16). Some studies, however, suggest that
newer antifungal formulations such as echinocandins and lipo-
somal formulations of AMB are much more active against
Candida biofilms (2, 21).
Although biofilm-forming ability is a major pathogenic at-
tribute of this ubiquitous fungus, its properties including the
mechanisms of resistance to antifungals have yet to be defined.
Previous workers have postulated factors such as lower metabolic
activity, contact-induced gene expression, the presence of an ex-
tracellular matrix, and persister cells as possible reasons for bio-
film-associated antifungal resistance (for a recent review, see ref-
erence 35). In the latter studies, the NCCLS microdilution assay
has been commonly used for MIC determination for planktonic-
mode Candida while alternative colorimetric assays such as the
3-(4-5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide and
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)car-
bonyl]-2H-tetrazolium hydroxide (XTT) reduction assays have
been used by a few for the same purpose (11, 16). On the con-
trary, colorimetric assays have been the cornerstone of MIC de-
termination for the biofilm mode of Candida. According to the
current methodology, the planktonic MIC is compared with that
for 24- or 48-h biofilms (10, 16, 23, 32).
It is noteworthy, however, that the NCCLS M-27A mi-
crodilution assay used conventionally for MIC determina-
tion for Candida was originally designed for a standard
concentration of the planktonic mode of Candida (0.5  103
cells/ml) (27). Nevertheless, the Candida biofilm cell density
after 24 or 48 h is far greater than 0.5  103 cells/ml and it
is tempting to speculate that the reported antifungal resis-
tance of biofilms may be due to the increased cell mass of
biofilms. Indeed, in a recent article, a claim has been made
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that cell density does affect the antifungal resistance of
Candida (28).
Furthermore, there is also an anomaly with regard to the age
of the cells subjected to antifungal susceptibility testing; i.e.,
NCCLS MIC determination for planktonic-mode cells is per-
formed with fresh cultures whereas a 24- or 48-h-old cell pop-
ulation is used for the biofilm mode. Hence, it could be sur-
mised that cellular aging could contribute to acquired higher
drug resistance in Candida biofilms.
Therefore, the aim of this study was to investigate the roles
of cell density and cellular aging on the comparative antifungal
susceptibilities of planktonic, biofilm, and biofilm-derived
planktonic cells (BDPC) of Candida. Furthermore, we also
investigated the effects of growth medium and incubation time
with drugs on the relative MICs for the planktonic versus the
biofilm mode of Candida.
MATERIALS AND METHODS
Organisms and growth conditions. Two strains of Candida albicans, namely, a
reference strain, ATCC 90028, obtained from the archival collection of the Oral
Biosciences laboratory of the Faculty of Dentistry, The University of Hong Kong,
and a wild-type (WT) clinical strain, BF-1, used previously for biofilm studies in
our laboratory, were used for this study (18, 19). The identities of the yeast
isolates were confirmed with the commercially available API 32C identification
system (BioMe´rieux, Marcy l’Etoile, France). Both Candida strains were subcul-
tured on Sabouraud dextrose agar (SDA; Gibco Ltd., Paisley, United Kingdom)
and maintained at 4°C during the experimental period. Culture purity was con-
firmed periodically by Gram stain visualization and the germ tube test.
Antifungal agents. Five antifungals commonly used to treat oropharyngeal and
systemic candidiasis were selected for this study, viz., caspofungin (CAS) from
Merck and nystatin (NYT), AMB, KTC, and flucytosine (5FC) from Sigma.
Antifungal agents were prepared as previously described (1).
Determination of MICs for planktonic Candida cells. First we determined the
MICs of the antifungals CAS, NYT, AMB, KTC, and 5FC for two Candida
strains with the standard NCCLS (now known as the Clinical and Laboratory
Standards Institute [CLSI]) criteria (27). Briefly, inocula from 24-h yeast cultures
on SDA were standardized to a turbidity equivalent to a 0.5 McFarland standard
at 520 nm with a spectrophotometer. The suspensions were further diluted in
Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies, New
York, NY) to yield an inoculum concentration of approximately 0.5  103 to
2.5  103 cells/ml. The MIC assay was performed with 96-well plates (Iwaki,
Tokyo, Japan), and each of the Candida species was exposed to a double dilution
of the aforementioned antifungals. The plates were incubated at 35°C for 48 h to
evaluate MICs.
Furthermore, MICs for planktonic Candida cells were also determined ac-
cording to the Antifungal Susceptibility Testing Subcommittee of the European
Committee on Antibiotic Susceptibility Testing (AFST-EUCAST) method (13).
The EUCAST method uses RPMI 1640 medium supplemented with 2% glucose
as the test medium and an inoculum concentration of 0.5  105 to 2.5  105
cells/ml. Each of these experiments was performed on three different occasions.
Preparation of standard yeast cell suspensions for biofilm studies. Candida
cells were grown in SDA medium at 37°C for 18 h. A loopful of the yeast was
then inoculated into yeast nitrogen base (YNB; Difco) medium supplemented
with 50 mM glucose in a rotary shaker at 75 rpm. After overnight broth culture,
the yeast cells were harvested in the late exponential growth phase and washed
twice with 20 ml of phosphate-buffered saline (PBS; pH 7.2, 0.1 M) prior to use
in the biofilm studies.
Biofilm formation. Candida biofilms were developed according to a previously
published protocol (18, 19). In brief, washed yeast cells were resuspended in
YNB medium supplemented with 100 mM glucose and adjusted to an optical
density at 520 nm of 0.38 (1  107 cells/ml). The standard cell suspension was
used immediately to develop biofilms on commercially available presterilized
96-well polystyrene plates (Iwaki, Tokyo, Japan). First, 100 l of a standardized
cell suspension (1 107 cells/ml) was pipetted into each well of a microtiter plate
and incubated for 1.5 h at 37°C in a shaker at 75 rpm to permit yeast adherence
to the well surface (adherence phase). For controls, a well of each microtiter
plate was handled in an identical fashion except that no Candida suspension was
added. Following the adhesion phase, the cell suspensions were aspirated and
each well was washed with 100 l of PBS to remove loosely adherent cells. A
200-l volume of YNB medium with 100 mM glucose was then pipetted into
each of the washed wells, and the plates were incubated at 37°C in a shaker at 75
rpm for 48 h. After the 48-h growth phase, microscopic examination of the
cultures was performed to rule out contamination.
Antifungal susceptibility test (AST) for Candida biofilms. ASTs of Candida
biofilms were carried out as previously described (32). After 48 h, the suspending
medium was aspirated and biofilms were washed with 100 l PBS to remove the
nonadherent cells. The stock solutions were diluted twofold with RPMI 1640
medium supplemented with 2% glucose to obtain drug concentrations of 100 to
0.1 g/ml for CAS, 240 to 0.225 g/ml for AMB, 64 to 0.125 g/ml for NYT and
KTC, and 420 to 0.4 g/ml for 5FC. A total of 100 l of the drug solution was
added to the microtiter plate containing Candida biofilms. Biofilms were then
incubated at 37°C for 24 or 48 h with the antifungals, and afterwards the
metabolic activity of fungal cells was determined by the XTT reduction assay
with minor modifications (18, 32).
XTT reduction assay. The XTT reduction assay used was a modification of the
methods described previously (18, 19, 32). Briefly, an XTT (Sigma, St. Louis,
MO) solution (1 mg/ml in PBS) was prepared, filter sterilized through a 0.22-
m-pore-size filter, and stored at 70°C. A menadione (Sigma) solution (0.4
mM) was prepared and filter sterilized immediately before each assay. Prior to
each assay, the XTT solution was thawed and mixed with the menadione solution
at a ratio of 5 to 1 by volume.
The biofilms were first washed three times with 200 l of PBS, and then 200
l of PBS-XTT-menadione solution was added to each of the prewashed wells
and the control wells. The microtiter plate was then incubated in the dark for 3 h
at 37°C. Following incubation, 100 l of solution was transferred to new wells
and the color change in the solution was measured with a microtiter plate reader
(SpectraMAX 340 Tunable Microplate Reader; Molecular Devices Ltd., Sunny-
vale, CA) at 490 nm. The absorbance values for all new wells were read at 490
nm. The absorbance values for the controls were then subtracted from the values
for the test wells to eliminate spurious results due to background interference.
The MIC50 for biofilm Candida cells was defined as the lowest drug concen-
tration with a 50% reduction in opacity compared with the drug-free control. To
exclude the effect of the growth medium on the MIC endpoint for the biofilms,
we performed the antifungal assays with two different media, namely, RPMI 1640
medium supplemented with 2% glucose and YNB medium supplemented with
100 mM glucose. Each experiment was performed three times with four repli-
cates on separate occasions.
Determination of cell density in Candida biofilm and age-matched planktonic
cultures. Since the MICs of all of the antifungals tested were higher for the
biofilm mode of Candida compared to the planktonic mode, we queried whether
this increased resistance was an artifact due to the higher cell density of the
biofilms. Therefore, the cell densities of the developing biofilms were assessed by
CFU counting and spectrometric analysis as described previously (39). Candida
biofilms were developed as described above, and cell densities were determined
for the 24- and 48-h time points. Cell densities were also determined in parallel
for age-matched planktonic cultures that were propagated under identical con-
ditions, and identical initial inocula (107 cells/ml) were used for the biofilm
experiments.
Drug susceptibility testing with higher-density planktonic suspensions. Since
the aforementioned experiment revealed that the cell densities of the 24- and
48-h biofilms were higher than the standard inoculum concentration used for the
determination of MICs for planktonic Candida by either the NCCLS or the
EUCAST method, we surmised that the reported increase in antifungal resis-
tance of biofilm mode cells was due to the increased cell density. To further
investigate this possibility, we increased the cell density of the planktonic cultures
from 1  105 to 1  108/ml and conducted ASTs with the broth microdilution
assay as described earlier. Classical growth curves could be observed with a cell
concentration of 1  107/ml for MIC determination. However, once the cell
concentration increased beyond 1  108/ml, Candida suspension growth curves
were not clearly discernible due to the very high optical density of the suspen-
sions. Therefore, we repeated the ASTs of higher-inoculum Candida suspensions
(1  107 and 1  108 cells/ml) with XTT as described above. Drugs were serially
double diluted in 96-well microtiter plates, and high cell density planktonic
suspensions were added as described for the NCCLS method. All of the assays
were performed in parallel with both RPMI 1640 medium supplemented with
2% glucose and YNB medium supplemented with 100 mM glucose.
Antifungal susceptibility of C. albicans SC5314. The first set of experiments
described above indicated that, in the biofilm mode, both the reference and WT
C. albicans strains were resistant to CAS and AMB although the high-density
planktonic cultures were susceptible to both drugs. Since a claim has been made
in a recent report (28) that, in planktonic mode, C. albicans SC5314 drug
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resistance depends on cell density, we repeated the above-described experiments
with the same strain, C. albicans SC5314, used by the previous workers. Hence,
for the AST of planktonic-mode C. albicans SC5314, the NCCLS method and
high-density cultures (1  108 cells/ml) were used. C. albicans SC5314 biofilms
were formed as described above for 24 h, and cell density was determined by
CFU counting and spectrometric analysis. MICs for C. albicans SC5314 biofilms
were determined with the XTT reduction assay as described above.
Antifungal susceptibility testing of age-matched planktonic cultures. Next, we
asked what other factors, apart from cell density, could contribute to the higher
antifungal resistance seen in Candida biofilms compared to planktonic cultures.
Since biofilms are preincubated for 24 or 48 h before the addition of drugs, cell
aging may contribute to their antifungal resistance. Furthermore, it has been
reported that antifungal-resistant cell populations develop with the maturation
of Candida biofilms (10). Therefore, to explore this possibility, 1  107-cell/ml
standard suspensions were prepared as described above for biofilm experiments.
These suspensions were divided into two aliquots and propagated in the plank-
tonic and biofilm modes under identical conditions. Along with the biofilm,
age-matched planktonic cultures, for 24- and 48-h periods, were evaluated by
AST with the aforementioned XTT reduction assay.
Antifungal susceptibility of BDPC. Next, we evaluated whether the high an-
tifungal resistance of Candida cells in the biofilm mode of growth is due to a
phenotypic or a genotypic alteration of cells. We postulated that if the drug
resistance is a genetically acquired trait, then once biofilm cells are resuspended
in the planktonic mode, they should maintain the antifungal resistance acquired
in the biofilm mode. To evaluate this hypothesis, we grew Candida biofilms as
mentioned above. After 24 and 48 h, the biofilms were washed gently and scraped
and pipetted into a new 96-well microtiter plate containing serially double-
diluted drugs as described earlier. These BDPC were incubated with all of the
antifungals tested for either 24 or 48 h, and MICs were determined by XTT
reduction assay as described earlier.
RESULTS AND DISCUSSION
Biofilm formation is a major virulence attribute of Candida.
Since the pioneering work of Hawser and Douglas in 1994 (16),
higher antifungal resistance of Candida biofilms has been
shown by a number of other investigators (10, 23, 32). How-
ever, in these studies, the MICs of antifungals for the biofilm
mode of Candida derived from colorimetric assays such as the
XTT reduction assay were compared with those of planktonic-
mode Candida cells by using MICs derived by the NCCLS
microdilution method. The latter method uses planktonic-
mode Candida suspensions at concentrations of 1 103 to 1 
104 cells/ml for the antifungal assay. In contrast, the biofilm
mode Candida population used in the XTT reduction assay has
a much higher density. This casts doubt on the possibility that
the higher cell density in the biofilm mode is a contributory
factor in the higher MICs for the Candida biofilm mode, as
recently claimed by Perumal et al. (28).
Antifungal susceptibility of planktonic and biofilm mode
Candida by standard methodology. In the first set of experi-
ments in the present study, standard ASTs, i.e., the NCCLS
and EUCAST methods, were used to evaluate the MICs for
the C. albicans ATCC and WT strains. The MICs of all five
antifungals (viz., CAS, NYT, AMB, KTC, and 5FC) were lower
for both the ATCC and WT planktonic-phase C. albicans
strains compared with biofilm phase cells when evaluated by
either the NCCLS or the EUCAST method (Table 1). Thus,
our results are in agreement with previous reports that biofilms
are more resistant to antifungals. However, CAS, which has
been reported to be effective against the Candida biofilm mode
(2, 21, 38), was not particularly active against Candida biofilms
in our study, confirming the observations that the susceptibility
of Candida biofilms to CAS is variable, possibly due to resis-
tant strains (17, 37).
Antifungal susceptibility of high-density Candida planktonic
suspensions. Once Candida cell densities were determined
after the adhesion phase (i.e., 1.5 h), it was found that approx-
imately 105 cells/ml remained in each well of a 96-well plate
from an initial standard inoculum of 1  107 cells/ml. Subse-
quently, biofilm cell densities reached approximately 1  107
and 1  108/ml after 24 and 48 h, respectively (Fig. 1). When
we repeated the AST of planktonic-mode cells with a greater
inoculum concentration of 1  108 cells/ml, up to 8-, 256-, and
1,000-fold increased MICs of NYT, KTC, and 5FC, respec-
tively, were noted (Table 1). However, the MICs of CAS and
TABLE 1. MICs of antifungal agents for the planktonic versus biofilm modes of Candida
Drug and strain
MIC (g/ml)
NCCLS, 103
cells/ml
EUCAST, 105
cells/ml
Planktonic cells,
107/mla
Planktonic cells,
108/mla
Biofilm, 24 h,
107 cells/mla
Biofilm, 48 h,
108 cells/mla
CAS
ATCC 0.2 0.2 0.2 0.2 100 100
WT 0.2 0.2 0.2 0.4 100 100
AMB
ATCC 0.23 0.23 0.23 0.46 15 15
WT 0.23 0.23 0.46 0.93 30 30
NYT
ATCC 1 1 2 8 16 16
WT 2 2 2 16 32 32
KTC
ATCC 0.125 0.125 8 64 64 64
WT 0.125 0.125 16 64 64 64
5FC
ATCC 0.8 0.8 6.5 420 420 420
WT 0.8 0.8 6.5 420 420 420
a Determined by XTT reduction assay.
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AMB did not change significantly, even with the higher inoc-
ulum concentration of planktonic Candida. Thus, the MICs of
the latter two drugs were either similar to or one- to twofold
greater than the MICs at the lower inoculum concentration.
For instance, the MICs of CAS for the C. albicans WT strain at
1  108 and 1  105 cells/ml were 0.4 and 0.2 g/ml, respec-
tively (Table 1). Hence, it appeared that the resistance of
planktonic-mode Candida may depend on the cell density of
the suspensions under some circumstances, in particular, for
fungistatic drugs such as KTC and 5FC.
However, as shown above, although the higher inoculum
concentrations of planktonic Candida were susceptible to fun-
gicidal drugs such as CAS and AMB, their biofilm counterparts
having an equivalent cell density were resistant to the latter
drugs. Therefore, we could conclude that the higher antifungal
resistance seen in the Candida biofilm mode compared to the
planktonic mode is not solely due to the higher cell density. It
therefore appears that the nature of the antifungal plays a
critical role in determining the relative resistance of the biofilm
versus planktonic-mode Candida.
Our data confirm results of previous studies which showed
that high-density (107 cells/ml) planktonic-mode Candida cells
were susceptible to antifungals whereas biofilm mode cells
were resistant (4, 11). In contrast, Perumal et al. (28) recently
claimed that cell density is a major factor contributing to the
higher antifungal resistance of Candida biofilms. The latter
workers observed that high-density planktonic cultures of C.
albicans SC5314 (equal to biofilm cell concentrations) showed
a resistance to CAS and AMB similar to that of biofilm mode
cells.
Therefore, to explore the possibility of a strain variation
effect on antifungal susceptibility, we used the same C. albicans
strain, SC5314, for the next set of ASTs (24). When we com-
pared the antifungal MICs obtained by the NCCLS method for
the planktonic mode with those obtained for the biofilm mode,
higher MICs of all of the antifungal tested, i.e., CAS, AMB,
KTC, and 5FC, were observed (Table 2). However, once the
planktonic-mode C. albicans SC5314 concentration was in-
creased to 1  108 cells/ml, it was observed that the cells were
resistant to KTC and 5FC but not to CAS and AMB (Table 2;
Fig. 2 and 3). Hence, our data on CAS and AMB are in line
with previous studies (4, 11) but contradict the observations
reported by Perumal et al. (28). Nevertheless, our data on KTC
are in agreement with the observation of Perumal et al. (28)
that high-density planktonic-mode C. albicans cells are tolerant
of high azole drug concentrations. These discrepancies in re-
sults could be due to the modified experimental protocols used
in the studies. Therefore, it is imperative that standard proto-
cols be used by future workers in order to understand the
enigma of the antifungal resistance of Candida biofilms. Con-
sidering the data from the present and other, related, studies,
we could conclude that although the higher cell density seen in
the biofilm mode may partially contribute to antifungal resis-
tance, there are other, as-yet-undiscovered, factors which mod-
ulate this phenomenon. These factors may include the nature
of the antifungal, as well as contact-induced gene expression or
differentially expressed protein biomarkers related to the sur-
face-attached biofilm mode (26, 35, 36).
Another interesting observation of the present study is the
paradoxical effect shown by C. albicans strains for CAS (Fig.
2). Thus, growth of C. albicans could be observed at drug
concentrations higher than the MIC, i.e., 12.5 to 50 g/ml. This
FIG. 1. Histogram illustrating the relative variations in cell density
of Candida biofilms during maturation and of age-matched planktonic
cultures. Note the reduction in the initial inoculum concentration of
1  107 to 1  105 cells/ml in the adhesion phase due to the removal
of nonadherent cells.
TABLE 2. MICs determined by the NCCLS method and AST of
planktonic-mode and 24-h biofilm C. albicans SC5314 cells
Drug
MIC (g/ml)
NCCLSa Planktonicmodeb 24-h biofilm
c
CAS 0.2 0.2 100
AMB 0.23 0.46 32
KTC 0.125 64 64
5FC 0.8 420 420
a 103 cells/ml.
b 108 cells/ml.
c 107 cells/ml.
TABLE 3. Comparative MICs of antifungal agents for 24- and 48-h
planktonic, biofilm, and biofilm-derived planktonic Candida cells
Drug and
strain
MIC (g/ml)
Planktonic cells Biofilm cells BDPC
24 h 48 h 24 h 48 h 24 h 48 h
CAS
ATCC 0.2 0.4 100 100 0.2 0.4
WT 0.4 0.4 100 100 0.4 0.2
AMB
ATCC 0.46 0.46 16 16 0.46 1.87
WT 0.93 0.93 32 32 1.87 3.75
NYT
ATCC 2 8 16 16 2 8
WT 4 16 32 32 4 16
KTC
ATCC 8 64 64 64 64 64
WT 16 64 64 64 64 64
5FC
ATCC 420 420 420 420 420 420
WT 420 420 420 420 420 420
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observation is in agreement with previous reports on the par-
adoxical growth of C. albicans in the presence of echinocandin
drugs (9, 25). Although several hypotheses have been proposed
to explain this phenomenon, the exact mechanism(s) has yet to
be found.
Antifungal susceptibility of age-matched planktonic cells
and biofilms. To evaluate the effect of cell aging on MICs, we
performed relative antifungal susceptibility testing with age-
matched biofilm and planktonic-mode Candida cells kept un-
der identical conditions for up to 24 and 48 h (age matched
refers to the incubation period for which two growth modes of
Candida were propagated; however, it should be noted that,
due to the disparate growth rates of the biofilm and planktonic-
mode cells, the quality of the resultant cell populations at 24 or
48 h is unlikely to be the same). When an AST of the afore-
mentioned age-matched planktonic cultures at 24 or 48 h was
performed, we found a MIC profile very similar to that of
high-density planktonic cultures (Table 3). For instance, higher
MICs of the fungistatic drugs KTC and 5FC and lower MICs of
CAS and AMB were noted. As the cell density of planktonic
cultures increases after 24 or 48 h, this may have been a
contributory factor in the lower susceptibility to fungistatic
drugs. In contrast, the MICs of CAS and AMB for respective
age-matched biofilm mode cells of Candida were relatively
higher (Table 3). It is known that aging Candida cells or cul-
tures enter into a stationary phase and, in doing so, acquire a
degree of resistance to antifungals (7, 8, 40). However, our
data indicate that the antifungal susceptibility of aged cultures
varies, depending on the antifungals as well as the growth
mode (Table 3). Taken together, it could be surmised that
factors other than cellular aging play a role in the higher
antifungal resistance of Candida cells in the biofilm mode.
Effect of culture medium and incubation period on antifun-
gal susceptibility. In order to determine whether the difference
in the medium or incubation time used could affect the relative
MICs of drugs for planktonic versus biofilm mode Candida
cells, we used two different media and incubation times for our
AST. We noted that for planktonic and biofilm cells, incuba-
tion for either 24 or 48 h with the antifungals tested yielded
almost identical results (data not shown). Furthermore, incu-
bation in RPMI 1640 medium with 2% glucose or YNB me-
dium with 100 mM glucose had no effect on the MICs for
FIG. 2. XTT reduction assay of resistance of high-density (108 cells/ml) planktonic cultures of C. albicans SC5314 and WT BF-1 to CAS (lines
1 to 4) and AMB (lines 5 to 8). Note the paradoxical effect of C. albicans strain resistance to CAS at higher concentrations (12.5 to 50 g/ml).
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either planktonic or biofilm cells (data not shown). It should be
noted that, on occasion, the culture medium and incubation
period resulted in a deviation of the MIC by 1 dilution. Hence,
we could exclude the quality of the culture medium used or
the incubation period as a possible contributory factor in the
higher MICs seen in our AST of Candida biofilms.
Antifungal susceptibility of BDPC. Next, to evaluate the
possibility that the high resistance seen in Candida biofilms is
a phenotypic or a genotypic feature, we performed an AST on
BDPC. We collected biofilm cells after 24 and48 h and trans-
ferred the cells into wells of a new 96-well plate, changing the
cells to the planktonic mode. The antifungal susceptibility of
these BDPC was almost identical to that of 48-h planktonic
Candida suspensions, except for AMB, to which cells were
more resistant (Table 3). Thus, the MIC of AMB for BDPC of
C. albicans ATCC 90028 was 1.87 g/ml, compared with 0.46
g/ml for the corresponding 48-h planktonic cultures.
Only a few studies thus far have compared the antifungal
susceptibilities of biofilm cells and BDPC (4, 5, 20, 28, 30).
Although it is difficult to draw firm conclusions due to differ-
ences in the methodologies, antifungal agents, and strains em-
ployed in these studies, the general consensus is that antifungal
FIG. 3. XTT reduction assay of resistance of high-density (108 cells/ml) planktonic cultures of C. albicans SC5314 to CAS (lines 1 and 2), AMB
(lines 3 and 4), KTC (lines 4 to 6), and 5FC (lines 7 and 8).
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resistance is a phenotypic feature rather than a genotypic al-
teration of biofilm cells. However, it is noteworthy that some
workers have shown that there is a small subpopulation of
biofilm cells known as persisters with higher antifungal resis-
tance than the rest of the biofilm population (15, 20, 22).
Hence, the marginal increase in the resistance of BDPC to
antifungals observed in our study may be due to the presence
of these persisters or another trait acquired through the bio-
film life-style.
In conclusion, we have carried out a comprehensive study of
comparative testing of the antifungal susceptibility of plank-
tonic cells, biofilm cells, and BDPC to five antifungals in clin-
ical use. Our study revealed that NCCLS or EUCAST deter-
minations alone are insufficient to obtain a holistic picture of
antifungal susceptibility, especially when the organisms are in
the biofilm mode. Therefore, it is imperative to determine the
MICs of antifungals at a higher cell density of the planktonic
and biofilm modes. Data from such a protocol will perhaps be
more useful particularly in clinical settings to select an appro-
priate antifungal. Furthermore, it could be concluded that al-
though physical factors such as cell density, cellular aging, and
growth medium may partially contribute to the higher antifun-
gal resistance seen in Candida biofilms, there are other factors
related to the biofilm mode which determine its higher anti-
fungal resistance. Current studies with newer molecular biol-
ogy tools and genomic and proteomic approaches should elu-
cidate the intriguing and as-yet-undiscovered aspects of the
antifungal resistance of candidal biofilms.
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